Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 16, 2026HematoOpen Access

Blastic Plasmacytoid Dendritic Cell Neoplasm in the Era of Targeted Therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

UTUgo Testa

Discussion

Loading...

Member takes

Overview

Randomized trial shows targeted therapies improve outcomes in patients with blastic plasmacytoid dendritic cell neoplasm, suggesting potential for better survival options.

Key Points

  • The aim is to evaluate the efficacy of targeted therapies in blastic plasmacytoid dendritic cell neoplasm compared to traditional chemotherapy.
  • Assess multiple organ involvement including skin, bone marrow, and lymph nodes.
  • Classify disease based on tumor location: skin-only, systemic-only, or both.
  • Utilize CD123-targeted therapies and chemotherapy regimens based on patient fitness.
  • Targeted therapies like Tagraxofusp and Pivekimab sunirine show a positive impact on patient survival.
  • Patients receiving targeted therapies demonstrated reduced chemotherapy-related toxicities.
  • Bridging patients to hematopoietic stem cell transplantation significantly increased long-term survival potential.

Cite This Study

Ugo Testa (2026) studied this question.

synapsesocial.com/papers/6a080acea487c87a6a40ccc9https://doi.org/10.3390/hemato7020015
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm2026 · 8 citations
  2. 2Real-world use of venetoclax and hypomethylating agents (HMA) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): A multi-institutional case series2025 · 1 citations
  3. 3Blastic Plasmacytoid Dendritic Cell Neoplasm (<scp>BPDCN</scp>): 2025 Update on Diagnosis, Pathophysiology, Risk Assessment, and Management2025 · 9 citations
  4. 4Sex-Biased <i>ZRSR2</i> Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis2021 · 88 citations
  5. 5Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasm2019 · 61 citations